secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001193125-21-318435
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q3 net loss $6.6M; cash $312.8M post-$198.7M IPO
-----------------------------------------------------------------

- Cash and equivalents $312.8M as of Sep 30, 2021, up from $15.2M at Dec 31, 2020.
- Net loss of $6.6M ($0.72/sh) for Q3 2021 vs $2.3M ($1.47/sh) in Q3 2020.
- Nominated TYRA-200 (FGFR2 inhibitor) for clinical development; IND expected 2H 2022.
- Appointed Esther van den Boom CFO, John Healy GC, Allison Kemner VP, Rehan Verjee to board.
- R&D expenses $5.5M (up from $1.9M) driven by pipeline advancement and personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312521318435/0001193125-21-318435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312521318435/d223896d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-318435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer